Brokers Set Expectations for C4 Therapeutics Q2 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Stock analysts at Brookline Capital Management issued their Q2 2025 EPS estimates for shares of C4 Therapeutics in a note issued to investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann expects that the company will post earnings of ($0.39) per share for the quarter. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share.

C4 Therapeutics (NASDAQ:CCCC) last posted its earnings results on Thursday, February 27th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05). The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $4.43 million. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%.

Several other equities analysts have also weighed in on CCCC. Stephens initiated coverage on shares of C4 Therapeutics in a report on Monday, November 18th. They set an “equal weight” rating and a $4.00 target price on the stock. Wells Fargo & Company upgraded shares of C4 Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $8.00 to $12.00 in a report on Thursday, December 19th. Finally, UBS Group upgraded shares of C4 Therapeutics to a “hold” rating in a report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.50.

C4 Therapeutics Trading Down 11.4 %

NASDAQ:CCCC opened at $2.40 on Monday. The firm has a market capitalization of $169.41 million, a price-to-earnings ratio of -1.41 and a beta of 2.95. The firm’s fifty day simple moving average is $3.48 and its 200 day simple moving average is $4.77. C4 Therapeutics has a twelve month low of $2.38 and a twelve month high of $11.88.

Hedge Funds Weigh In On C4 Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CCCC. Aigen Investment Management LP acquired a new position in C4 Therapeutics in the 3rd quarter worth $82,000. LMR Partners LLP acquired a new stake in shares of C4 Therapeutics in the 3rd quarter valued at about $291,000. Intech Investment Management LLC acquired a new stake in shares of C4 Therapeutics in the 3rd quarter valued at about $155,000. The Manufacturers Life Insurance Company raised its stake in shares of C4 Therapeutics by 81.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 41,664 shares of the company’s stock valued at $237,000 after purchasing an additional 18,746 shares in the last quarter. Finally, FMR LLC raised its stake in shares of C4 Therapeutics by 687.0% in the 3rd quarter. FMR LLC now owns 185,941 shares of the company’s stock valued at $1,060,000 after purchasing an additional 162,314 shares in the last quarter. Institutional investors and hedge funds own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.